VERV - Why Verve Therapeutics Deserves A Spot On Your Watchlist
2024-06-13 06:44:46 ET
Summary
- Verve Therapeutics focuses on gene editing technology for one-dose therapies to reduce lipid levels related to ASCVD.
- VERV's pipeline includes therapies targeting genes like PCSK9, ANGPTL3, and LPA to lower ASCVD risk.
- Verve's leading programs, VERVE-101 and VERVE-102, target heterozygous familial hypercholesterolemia (HeFH), with VERVE-101 in clinical trials and VERVE-102 in the IND-enabling stage.
- Financially, Verve has a strong cash position, with $606.3 million in liquidity and a cash runway of approximately 3.5 years.
- VERV's research is in the early stages, making it a speculative investment, but it is worth adding to a watchlist as research progresses.